News

All news CSR Events General PERSONAL CARE Press release Products & Technologies Protéus

CELLforCURE launches a process to find a buyer for its Les Ulis site

CELLforCURE, a subsidiary of the SEQENS Group, has informed its employee representatives of its decision to look for a potential buyer for its site in Les Ulis (Essonne). CELLforCURE specializes in the development and the contract manufacturing of Cell & Gene therapies.

SEQENS to launch PeptiCode™ HP-9: the first European biotech Hexapeptide-9

Sale of our Limoges Botanical Actives and In Vitro Diagnostics activities to Solabia

SEQENS new antiwear additive ROSCAN® 6253NV is registered on the LUSC list.

Pharma

Brenntag and SEQENS partner for the commercialization of non-GMP pharmaceutical intermediates in Europe

BBG Advanced Therapies and CELLforCURE partner to provide transatlantic manufacturing solutions for ATMPs

CELLforCURE by SEQENS to Manufacture Galapagos’ CAR T-Cell Therapy Candidates for Upcoming Trials

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

SEQENS and Novonesis announce strategic partnership for enhancing customer’s access to industrial biocatalytic processes

SEQENS announces the appointement of a new CEO

SEQENS and APPLEXION announce strategic partnership for the distribution of SEQENZYM FT

Smart Immune and CELLforCURE by SEQENS partner to industrialize SMART101 clinical batches manufacturing

Arkema Grants an Exclusive Technology License to SEQENS to manufacture PEKK

1 2 3